Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation

<p dir="ltr">A hybrid pharmacophore model, based on structural motifs previously identified by our team, was employed to generate ligands that simultaneously target COX-2, 15-LOX, and PPARγ in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). Notable COX-2...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Mai S. El-Shoukrofy (19646815) (author)
مؤلفون آخرون:	Azza Ismail (10180577) (author), Reem H. Elhamammy (20448346) (author), Sherien A. Abdelhady (20837720) (author), Rasha Nassra (10180574) (author), Monica S. Makkar (20837723) (author), Mahmoud A. Agami (20837726) (author), Ahmed Wahid (15599036) (author), Hisham A. Nematalla (14798362) (author), Minh Sai (17049279) (author), Daniel Merk (1373682) (author), Ahmed F. El-Yazbi (10180589) (author), Ahmed S.F. Belal (20837729) (author), Ali H. Eid (5461829) (author), Perihan A. Elzahhar (10180568) (author)
منشور في:	2025
الموضوعات:	Biomedical and clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Thiazolones PPARγ COX-2 15-LOX Multi-targeting Liver inflammation Metabolic diseases
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation

مواد مشابهة